S&P 500 Healthcare Sector SEC Filings — April 21, 2026

21-04-2026

Equitable Financial Life Insurance Co, an indirect wholly owned subsidiary of Equitable Holdings, Inc., filed an S-1/A pre-effective amendment No. 1 on April 21, 2026 (SEC file 333-293448), to register securities related to the Market Stabilizer Option® (MSO), an index-linked investment option under certain variable life insurance policies. The MSO offers participation in the S&P 500 Price Return Index up to a company-set Growth Cap Rate (minimum 6%), with 0% return if Index performance is between 0% and the cap, full cap if above, and downside protection to -25% (full losses beyond that). Key risks include early distribution adjustments causing principal loss, no transfers/withdrawals from segments before maturity, and dependence on the company's claims-paying ability.

• ·MSO Segment Term approximately one year; no transfers or partial withdrawals allowed before Segment Maturity Date.
• ·Filer details: Central Index Key 0000727920, EIN 13-5570651, incorporated in NY, fiscal year end Dec 31.
• ·Equitable Financial Life Insurance Company of America organized 1969 in Arizona; Equitable Financial Life Insurance Co doing business since 1859.
• ·Registered for delayed or continuous offering pursuant to Rule 415.
• ·Prospectus dated May 1, 2026.

21-04-2026

Hanmi Financial Corporation reported Q1 2026 net income of $22.6 million ($0.75 per diluted share), up 6.2% from $21.2 million in Q4 2025, driven by net interest income growth to $63.2 million, NIM expansion to 3.38%, deposits increase of 1.8% to $6.8 billion, and improved asset quality with NPAs at 0.16% of total assets. ROAA and ROE strengthened to 1.18% and 10.86%, respectively, while capital ratios improved with tangible common equity to tangible assets at 10.11%. However, total assets declined 0.4% to $7.84 billion, loans decreased 0.3% to $6.55 billion, interest income on loans fell 2.8%, and credit loss expense rose to $2.9 million from $1.9 million.

• ·Loan production increased 0.8% QoQ to $377.9 million, with C&I loan production up 64%.
• ·Noninterest-bearing demand deposits stable at 30% of total deposits.
• ·Returned $13.4 million to shareholders: $8.6 million dividends and $4.8 million share repurchases.
• ·SBA loans sold: $32.5 million at 7.88% premium (up from $29.9 million at 7.40%).
• ·Average loans to average deposits ratio: 97.5% (up from 96.6%).

21-04-2026

Core Scientific, Inc. announced a proposed private offering of $3.3 billion aggregate principal amount of senior secured notes due 2031 by its indirect subsidiary Core Scientific Finance I LLC, guaranteed by its subsidiary guarantors. The Issuer intends to use a substantial portion of the net proceeds to pay a distribution to the Company, which plans to repay in full its outstanding delayed draw term loans, including accrued interest, under the Delayed-Draw Bridge Credit Agreement dated March 4, 2026 (amended March 18, 2026). The offering targets qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.

• ·Notes issued by Core Scientific Finance I LLC, an indirect subsidiary of the Company; Company not issuing or guaranteeing the Notes.
• ·Delayed-Draw Bridge Credit Agreement dated March 4, 2026, as amended by Amendment No. 1 dated March 18, 2026, with Morgan Stanley Senior Funding, Inc. as administrative agent and collateral agent.
• ·Filing includes Exhibit 99.1 (Press Release dated April 21, 2026) and Exhibit 99.2 (Supplemental Information for potential investors).

21-04-2026

UnitedHealth Group reported Q1 2026 revenues of $111.7 billion, up 2% YoY from $109.6 billion, with UnitedHealthcare revenues growing 2% to $86.3 billion and operating margin expanding 40 basis points to 6.6%; however, Optum revenues dipped slightly to $63.7 billion from $63.9 billion with earnings declining to $3.3 billion from $3.9 billion, operating cost ratio rose to 13.8% from 12.4%, and earnings from operations fell to $9.0 billion from $9.1 billion. The company raised its full-year 2026 adjusted earnings outlook to greater than $18.25 per share, announced the acquisition of Alegeus Technologies (expected earnings neutral), completed the sale of Optum UK for $400 million in net proceeds, and plans to repurchase at least $2 billion in stock by end-Q2.

• ·Medical care ratio improved to 83.9% from 84.8% YoY (down 90 basis points).
• ·Days claims payable 48.6 (up from 45.5 YoY); days sales outstanding 21.6 (down from 22.3 YoY).
• ·Debt-to-capital ratio 42.9% as of March 31, 2026 (down from 44.6% YoY).
• ·UnitedHealthcare Medicare & Retirement seniors served declined by 965,000 in Q1 2026.
• ·UnitedHealthcare Community & State people served contracted by 220,000 in Q1 2026.
• ·Optum Rx adjusted scripts 383 million vs 408 million YoY.

21-04-2026

Synchrony Financial furnished its Monthly Charge-Off and Delinquency Statistics as of and for each of the thirteen months ended March 31, 2026, in Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. The company intends to continue providing these statistics monthly, with the last month of each calendar quarter furnished alongside quarterly financial results announcements. This information is not deemed 'filed' for liability purposes.

• ·Filing date: April 21, 2026
• ·Statistics cover thirteen months ended March 31, 2026
• ·Securities registered on New York Stock Exchange

21-04-2026

James Reed Financial Services, Inc. filed its 13F-HR report as of March 31, 2026, disclosing 17 equity holdings with a total market value of $115,512,810,000. The portfolio is concentrated in ETFs such as iShares TR MSCI USA SZE FT ($26,146,082,000), Vanguard Index FDS Large CAP ETF ($25,621,737,000), J P MORGAN EXCHANGE TRADED F NASDAQ EQT PREM ($23,389,877,000), and individual stocks including Apple Inc ($1,134,188,000) and Microsoft Corp ($1,212,307,000). All positions are held solely with sole investment discretion and voting authority.

• ·Filing date: April 21, 2026
• ·Report period end: March 31, 2026
• ·All holdings reported as SH SOLE with sole voting authority (2474 shares 3M, 1034 Amazon, 905 Amgen, 4469 Apple, 586128 Capital Group, 2053 Exxon, 30413 Global X Artificial ETF, 163966 iShares MSCI USA, 421287 JPM EQ Prem, 1684 JPM Chase, 3275 Microsoft, 4488 NVIDIA, 3440 Progressive, 85734 Vanguard Large Cap, 52181 Vanguard Mid Cap, 430 Vanguard S&P 500, 2450 Vanguard Russell 1000 Growth)

21-04-2026

AA Financial Advisors, LLC filed a 13F-HR disclosing holdings in 221 securities with a total market value of $709,887,826,000 as of March 31, 2026. The portfolio features significant allocations to ETFs such as Capital Group Dividend Value ETF ($34.2B), Vanguard Index Fds Small Cp ETF ($33.5B), and Dimensional ETF Trust US Core Equity 2 ($28.8B), alongside individual stocks like Apple Inc., Microsoft Corp., and Nvidia Corporation. All reported positions are held with sole investment discretion and sole voting power.

• ·Filing date: April 21, 2026
• ·Report period end: March 31, 2026
• ·Business address: 150 E Broad St., Suite 100, Columbus, OH 43215
• ·Phone: 614-442-3355
• ·SEC file number: 028-24043
• ·All holdings reported as SH SOLE with sole voting power

21-04-2026

CID Holdco, Inc. filed definitive additional proxy materials (DEFA14A) attaching a Form 8-K detailing entry into financing agreements with White Lion Capital, LLC on April 17, 2026, including a Common Stock Purchase Agreement for up to $10,000,000 of common stock and a Note Purchase Agreement for up to $2,875,000 principal ($2,300,000 proceeds at 20% OID) in monthly tranches. The agreements require stockholder approval by May 15, 2026, to exceed the Nasdaq 19.99% exchange cap, with $120,000 in commitment shares and potential $250,000 liquidated damages for delays in registration or approval. No operational or financial performance metrics or period-over-period comparisons are provided.

• ·Effective Date of financing agreements: April 17, 2026
• ·CSPA Commitment Period: April 17, 2026 to December 31, 2028
• ·First note tranche closing: within one trading day after SEC registration statement filing
• ·Stockholder record date for proxy materials: March 23, 2026
• ·Notes mature 6 months after each tranche funding date
• ·Notes subordinated to J.J. Astor loan until discharged
• ·Company is an emerging growth company

21-04-2026

News Corporation filed an 8-K disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program for Class A (NWSA) and Class B (NWS) common stock, as attached in Exhibits 99.1 and 99.2. The program authorizes repurchases from time to time, with daily disclosures required by ASX rules if transactions occur. No specific repurchase transactions are detailed in the filing.

• ·Filing date: April 21, 2026; Earliest event date: April 20, 2026
• ·Securities: Class A Common Stock (NWSA) and Class B Common Stock (NWS) on Nasdaq Global Select Market

21-04-2026

Verus Financial Partners, Inc., based in Richmond, VA, filed its 13F-HR disclosing $1,114,955,862 in total holdings across 121 positions as of March 31, 2026. The portfolio is diversified with heavy emphasis on passive ETFs, led by Vanguard Total Stock Market (267780264 value) and Vanguard Total Bond Market (131527459 value), alongside Dimensional and iShares funds. No prior period data is provided in the filing.

• ·Filing Date: April 21, 2026
• ·Report Period End: March 31, 2026
• ·State of Incorporation: VA
• ·SEC File Number: 028-13642
• ·Former Name: Kuehl Shepherd Kozlowski & Associates, Inc. (name change 2010-01-21)

21-04-2026

LifeWealth Investments, LLC filed a 13F-HR on April 21, 2026, disclosing its institutional holdings as of March 31, 2026, with a total portfolio value of $335042535 across 141 positions, all held as sole ownership. The largest holding is iShares Russell Top 200 Growth ETF valued at $32926892 (132322 shares), followed by iShares Russell Top 200 Value ETF at $21180188 (228555 shares) and Capitol Series Trust Sterling Capital Enhanced Equity at $19138773 (762957 shares). No period-over-period changes are disclosed in this filing.

• ·All positions held as sole ownership (SH SOLE) with no shared, other, or none voting rights indicated.
• ·Firm address: 270 W. PLANT STREET, STE. 240, WINTER GARDEN, FL 34787.
• ·SEC file number: 028-25415; CIK: 0002033794.

21-04-2026

ABLE Financial Group, LLC filed its Form 13F-HR on April 21, 2026, disclosing 206 equity holdings as of March 31, 2026, primarily consisting of ETFs and individual stocks with sole voting power over all positions. Top holdings include Dimensional ETF Trust US Core Equity 2 valued at $26972104 (694084 shares), J P Morgan Exchange Traded F Municipal ETF at $24567486 (491448 shares), and iShares TR Core MSCI Intl at $18806156 (225035 shares). No prior period data or changes are provided in the filing.

• ·Report period end date: March 31, 2026
• ·Filed as of date: April 21, 2026
• ·All positions reported with sole voting power (SH SOLE); no shared or other voting power indicated
• ·Central Index Key: 0001977500
• ·SEC file number: 028-23246

21-04-2026

Randall & Associates Wealth Management filed a 13F-HR report disclosing 56 equity positions with a total market value of $148368433 as of March 31, 2026, all held on a sole discretionary basis. The filing, signed by Collin Randall (CCO), reflects no put/call positions or other voting authority. The firm, formerly known as Bennett Associates Wealth Management (name change effective February 13, 2024), manages these holdings from its office in Butler, PA.

• ·Filing date: April 21, 2026
• ·Report period end: March 31, 2026
• ·Business address: 122 South Washington Street, Butler, PA 16001
• ·SEC file number: 028-23862
• ·All positions held as SOLE with no shared voting or put/call activity

21-04-2026

Tanglewood Wealth Management, Inc. (CIK: 0001454308) filed its 13F-HR on April 21, 2026, disclosing $1207340732 in total holdings across 38 positions as of March 31, 2026. The portfolio emphasizes fixed income and international ETFs, with top holdings including iShares 3-7 Year Treasury Bond ETF ($189383043, 1596822 shares sole), Vanguard FTSE Developed Markets ETF ($186705782, 2913636 shares sole), and iShares 1-3 Year Treasury Bond ETF ($76981910, 932323 shares sole). Other positions include individual stocks such as Apple Inc. (2160 shares, $548186), Microsoft Corp. (1134 shares, $419773), and Berkshire Hathaway Inc. Del Cl A (1 share, $718140).

• ·SEC file number: 028-13327
• ·Adviser ID: 107639
• ·Business address: 1400 Post Oak Blvd, Suite 800, Houston, TX 77056
• ·All holdings reported as sole discretion with zero shared or other voting authority
• ·Berkshire Hathaway Inc. Del Cl A held at 1 share

21-04-2026

Danaher Corporation reported Q1 2026 sales of $5,951 million, up 3.7% YoY from $5,741 million, with strong growth in Biotechnology (+11.5% to $1,797 million) and Life Sciences (+3.3% to $1,737 million), though Diagnostics revenue declined 1.3% to $2,417 million and North America sales fell 4.1% to $2,478 million. Net earnings increased 7.9% to $1,029 million, with diluted EPS rising 9.8% to $1.45 from $1.32. However, comprehensive income dropped sharply to $643 million from $2,560 million, primarily due to $394 million in foreign currency translation losses.

• ·Total assets stood at $83,544 million as of March 27, 2026, up slightly from $83,464 million at year-end 2025.
• ·Recurring revenue increased 4.4% YoY to $5,031 million, representing 84.5% of total sales.
• ·No common stock repurchases in Q1 2026, compared to $1,078 million in Q1 2025.
• ·Cash and equivalents increased $1,086 million to $5,701 million, driven by operating cash flow and net borrowings.

21-04-2026

On April 20, 2026, Eduardo Martins, M.D., D.Phil., retired as Chief Medical Officer of Sagimet Biosciences Inc., effective immediately, and will continue as an external scientific advisor. The company appointed Andreas Grauer, M.D., as the new Chief Medical Officer, effective the same date. Dr. Grauer previously served as CMO at Omeros Corporation (October 2023 to April 2026), Federation Bio (October 2021 to July 2023), and Corcept Therapeutics (March 2019 to August 2021), with prior roles at Amgen and Procter & Gamble Pharmaceuticals.

• ·Dr. Grauer held Vice President Global Development role at Amgen from December 2008 to December 2018.
• ·Dr. Grauer is an Associate Professor of Medicine at the University of Heidelberg Medical School.
• ·Series A Common Stock has $0.0001 par value per share and trades as SGMT on Nasdaq Global Market.

21-04-2026

MSCI Inc. reported first quarter 2026 operating revenues of $850.8 million, up 14.1% YoY with organic growth of 13.3%, driven by 26.6% growth in asset-based fees and 8.6% in recurring subscription revenues. While the Index segment delivered strong 17.7% revenue growth and record asset-based fee run rate, Analytics grew 10.3%, Sustainability and Climate 8.6% with organic growth of only 3.7%, and All Other – Private Assets saw Adjusted EBITDA decline 3.5% despite 7.9% revenue growth. Operating margin expanded to 53.7%, Adjusted EBITDA margin to 59.3%, and diluted EPS surged 49.1% to $5.53, supported by a $88 million discrete tax benefit.

• ·Retention Rate of 95.4% in Q1 2026, up slightly from 95.3% in Q1 2025.
• ·Headcount increased 2.2% to 6,319 employees as of March 31, 2026.
• ·Cash dividend of $2.05 per share declared for Q2 2026, payable May 29, 2026.
• ·Full-Year 2026 guidance: Operating expenses $1,490-$1,530M; Adjusted EBITDA expenses $1,305-$1,335M; Free cash flow $1,470-$1,530M.
• ·Total debt to adjusted EBITDA ratio 3.2x as of March 31, 2026 (target 3.0x-3.5x).

21-04-2026

On April 16, 2026, the Board of Directors of Donnelley Financial Solutions, Inc. authorized a new share repurchase program for up to $150 million of the company's outstanding common stock, commencing April 17, 2026, and effective through December 31, 2027. This program replaces the prior $150 million authorization, which had approximately $15 million remaining. Repurchases will be at management's discretion based on market conditions and may utilize a Rule 10b5-1 plan.

• ·Common Stock: Par Value $0.01, Trading Symbol DFIN on NYSE
• ·Share repurchases may be conducted on the open market or in privately negotiated purchases

21-04-2026

On April 21, 2026, Zeo ScientifiX, Inc. (ZEO) filed an 8-K announcing a significant milestone: successful training of over 500 clinicians through its monthly Masterclass series in regenerative biologics treatments. The press release is attached as Exhibit 99.1.

21-04-2026

Citizens Financial Services, Inc. reported record 2025 net income of $36,572 thousand, up 31.5% YoY from $27,818 thousand in 2024, with improved net interest margin to 3.50% from 3.13%, efficiency ratio to 54.50% from 61.89% (86th percentile vs peers), and core ROAA to 1.21% (87th percentile). Total assets grew modestly 1.3% YoY to $3,064,564 thousand while loans rose 1.6% to $2,360,015 thousand, but deposits declined 0.2% to $2,376,979 thousand, lifting the loans-to-deposits ratio to 99.29%. Asset quality was stable with NPAs/assets at 0.95% (flat YoY) and NCOs/avg loans at 0.03% (down from 0.11%).

• ·Liquidity sources totaled $1,392,583 thousand as of Dec 31, 2025, including $636,189 thousand FHLB borrowing capacity.
• ·Core diluted EPS $7.62 in 2025, up from $5.94 in 2024; dividend per share $1.98.
• ·Fraud occurrences rose to 202 in 2025 from 104 in 2024, but customer losses fell to $8,867 from $141,496.
• ·Potential PA deposit outflows to stablecoins: $5.4B-$10.8B, leading to $4.6B-$9.3B drop in lending.

21-04-2026

Alpine Associates Management Inc. disclosed total holdings of $1,696,306,150 across 70 positions in its 13F-HR filing as of March 31, 2026. Top holdings include Norfolk Southern Corp valued at $133,298,585 (464,455 shares sole), Air Lease Corp at $89,766,950 (1,382,306 shares sole), and Chart Industries Inc at $88,644,891 (428,754 shares sole). No prior period comparisons or changes are provided in the filing.

• ·All 70 positions held with sole voting power (SH SOLE).
• ·Filing covers period ending March 31, 2026, submitted April 21, 2026.

21-04-2026

Worthington Financial Partners, LLC filed its Form 13F-HR on April 21, 2026, reporting holdings as of March 31, 2026, with a total value of $116397591 across 105 positions, all under sole discretionary voting authority. The portfolio is heavily weighted toward technology stocks including NVIDIA Corporation (830700 shares), Apple Inc (745400 shares), and Microsoft Corp (650300 shares), as well as various exchange-traded funds such as First Trust ETFs and ARK ETFs. No prior period comparisons or performance metrics are provided in the filing.

• ·Report period end date: 03-31-2026
• ·Filed as of date: 04-21-2026
• ·State of incorporation: OH
• ·Business address: 57 E. Wilson Bridge Rd #300, Worthington, OH 43085
• ·Business phone: 614-368-0769
• ·SEC file number: 028-26745
• ·Central Index Key: 0002111427

21-04-2026

Pacific Oak Strategic Opportunity REIT, Inc. disclosed via Form 8-K that its wholly-owned subsidiary, Pacific Oak SOR (BVI) Holdings, Ltd., filed IFRS consolidated and separate financial statements and an annual report with the Israel Securities Authority and Tel Aviv Stock Exchange for the year ended December 31, 2025. These English translations are furnished as Exhibits 99.1, 99.2, and 99.3 and relate to Series B and D bond offerings to Israeli investors since February 2020. The information is furnished, not filed, for SEC purposes.

• ·Bond offerings registered with Israel Securities Authority and listed on Tel Aviv Stock Exchange.
• ·Subsidiary financial statements prepared in accordance with IFRS.

21-04-2026

On April 15, 2026, the Board of Trustees of abrdn National Municipal Income Fund (VFL) approved a change to its non-fundamental investment policy, expanding the limit on investments in below-investment grade or equivalent unrated municipal obligations from 20% of net assets to 100% of assets, effective June 1, 2026. This Supplement No. 1, dated April 20, 2026 (re-filed April 21, 2026), updates the Joint Proxy Statement/Prospectus dated January 29, 2026, to reflect this alignment with MFS Municipal Income Trust's strategy, eliminating prior differences in principal investment strategies.

• ·Supplement re-filed on April 21, 2026, to correct typographical error from April 20, 2026 filing; no material changes.
• ·Joint Proxy Statement/Prospectus originally dated January 29, 2026.

21-04-2026

RCS Financial Planning, LLC filed a 13F-HR disclosing 98 equity positions totaling $192771542 as of March 31, 2026, all held with sole discretionary voting power. The portfolio is diversified across ETFs from providers including Dimensional ETF Trust, Fidelity, iShares, and Vanguard, alongside individual stocks such as Apple Inc (13129 shares valued at $3331918), CrowdStrike Holdings Inc Cl A (7836 shares valued at $3059253), and CSX Corp (13050 shares valued at $535703). No changes in holdings or voting power shares were reported in the filing.

• ·Filing submitted on April 21, 2026, for quarter ended March 31, 2026
• ·All 98 positions held as SH SOLE with 0 put/call shares and 0 other voting power
• ·Address: 130 Admiral Cochrane Dr, Ste 200-A, Annapolis, MD 21401

21-04-2026

Pacific Sage Partners, LLC disclosed $635,626,576 in total holdings value across 121 positions in its 13F-HR filing as of March 31, 2026. Top holdings include Schwab Strategic Trust INT-TERM U.S. TREAS ETF ($86,687,058, 3,480,010 shares), Microsoft Corp ($69,854,682, 188,710 shares), and BlackRock ETF Trust II iShares Flexible Income ETF ($60,921,457, 1,173,146 shares), with all positions held under sole voting and investment discretion. The portfolio features a mix of individual stocks, ETFs focused on treasuries, equities, and commodities, including a small put option position on Microsoft.

• ·Filing submitted on April 21, 2026, for quarter ended March 31, 2026.
• ·Heavy allocation to fixed income and treasury ETFs, including Vanguard Malvern Fds STRM INFPROIDX ($37,488,010) and Vanguard Scottsdale Fds SHORT TERM TREAS ($37,303,917).
• ·Includes commodity exposure via Sprott Physical Gold, Silver trusts and iShares Silver Trust.

21-04-2026

Financial Council, LLC filed its 13F-HR report disclosing 101 equity holdings with a total market value of $259,225,727,000 as of March 31, 2026. The portfolio is dominated by ETFs including top positions in Capital Group Global Growth Eqt Shs Creation Uni ($52,004,129,000; 1,558,410 shares), iShares TR MSCI ACWI ex US ($26,515,430,000; 387,256 shares), and Capital Group Growth ETF Shs Creation Uni ($19,521,104,000; 485,720 shares). All reported positions are held with sole voting and sole investment power; no period-over-period changes are disclosed in this filing.

• ·Report filed on April 21, 2026, for period ending March 31, 2026
• ·No shared voting power, no put or call options reported
• ·Firm address: 100 West Road, Suite 504, Towson, MD 21204
• ·Phone: 410-821-9200

21-04-2026

Parker Financial LLC filed its 13F-HR report disclosing total holdings of $250,281,466 across 37 positions as of March 31, 2026, with no indicated changes or options activity. The portfolio is dominated by ETFs including Vanguard Tax-Managed FDS VAN FTSE DEV MKT ETF ($51,085,337), Dimensional ETF Trust US Core Equity 2 ($37,533,277), Vanguard Index FDS Growth ETF ($28,696,904), and Vanguard Index FDS Value ETF ($26,293,874). Individual stock holdings include Apple Inc ($1,417,548), Microsoft Corp ($1,158,354), and Amazon.com Inc ($987,825).

• ·Report filed April 21, 2026
• ·All positions reported as ordinary shares (SH); no put/call options (OTR 0)
• ·Business address: 9230 Bayshore Dr NW, Ste 201, Silverdale, WA 98383

21-04-2026

Federal Home Loan Bank of San Francisco filed an 8-K on April 21, 2026, reporting under Item 2.03 the creation of a direct financial obligation via a consolidated obligation bond issued on trade date April 15, 2026, with a Bank par value of $15,000,000. The bond features a 4.000% fixed coupon, matures July 22, 2030, and has an optional principal redemption call on July 22, 2027 (European style). No period-over-period comparisons or performance metrics were provided in the filing.

• ·Trade Date: April 15, 2026
• ·Settlement Date: April 22, 2026
• ·Maturity Date: July 22, 2030
• ·Next Pay Date: July 22, 2026
• ·Next Call Date: July 22, 2027
• ·Call Type: Optional Principal Redemption
• ·Call Style: European
• ·Rate Type: Fixed Constant
• ·CUSIP: 3130BAEE3

21-04-2026

Axiom Financial Strategies, LLC filed its 13F-HR report on April 21, 2026, for the quarter ended March 31, 2026, disclosing 32 equity holdings with a total market value of $284089099. All positions are held on a sole basis with no reported changes or voting authority details indicating additions or reductions in this filing. Notable holdings include Franklin Templeton ETF TR Franklin Dyn Mun at $33125751, American Cnty ETF TR Intl Eqt ETF at $20529336, and Ishares TR Core S&P500 ETF at $58827368.

• ·Filing period end date: March 31, 2026
• ·All 32 holdings reported as sole discretionary with no shared voting or other manager authority
• ·Address: 101 West Spring St, 5th Floor, New Albany, IN 47150

21-04-2026

Quad-Cities Investment Group, LLC disclosed holdings totaling $250861098 across approximately 200 positions in its 13F-HR filing as of March 31, 2026, with sole discretionary voting power over all shares. Top holdings include Apple Inc. COM (14411504 value, 56785 shares), Amazon.com Inc COM (5687645 value, 27309 shares), and NVIDIA Corporation COM (4508747 value, 25853 shares). No period-over-period changes or performance metrics are provided in the filing.

• ·Filing submitted on April 21, 2026, for period ending March 31, 2026
• ·All positions held with sole voting power (SH SOLE); no shared or other voting power reported
• ·Business address: 5177 Utica Ridge Road, Davenport, IA 52807

21-04-2026

Tenon Financial LLC filed a 13F-HR on April 21, 2026, disclosing total holdings of $254,555,844 across 54 positions as of March 31, 2026. The portfolio is heavily weighted toward Vanguard ETFs, including the S&P 500 ETF ($59,403,541), Extended Market ETF ($51,699,715), and Total International Stock Index Fund ($43,651,175). Other notable positions include Apple Inc. ($3,821,637), Eli Lilly & Co. ($2,144,063), and Amazon.com Inc. ($1,716,978), with all holdings reported under sole voting authority.

• ·All 54 positions reported with sole voting authority (no shared or none)
• ·Filing CIK: 0002020781, SEC File Number: 028-24079
• ·Business address: 10 Station Place Suite 9, Metuchen, NJ 08840

21-04-2026

Blue Jean Financial LLC filed its 13F-HR on April 21, 2026, reporting holdings as of March 31, 2026, with a total portfolio value of $121,311,791,000 across 68 positions, all held with sole voting and dispositive power. Top holdings by value include Amazon.com Inc at $3,821,963,000, Apple Inc at $3,681,985,000, Alphabet Inc (Class C) at $3,481,907,000, Nvidia Corporation at $3,548,342,000, and Microsoft Corp at $3,382,613,000. No changes or performance metrics are disclosed in this snapshot filing.

• ·All 68 positions reported with 0 shared voting or dispositive power.
• ·Largest share position: Rocket Cos Inc (129208 shares), Zeta Global Holdings Corp (131737 shares).
• ·Portfolio includes ETFs (e.g., SPDR GOLD TR, iShares TR) and individual stocks across sectors.

21-04-2026

Newport Asia LLC filed its Form 13F-HR on April 21, 2026, reporting institutional equity holdings as of March 31, 2026. The filing metadata indicates zero sole shared ownership positions (SH SOLE: 0) with no specific securities or values detailed in the provided content. No period-over-period changes or performance metrics are present.

• ·Filing accession number: 0001104659-26-045916
• ·SEC file number: 028-16132
• ·Business address: 601 Montgomery Street, Suite 715, San Francisco, CA 94111

21-04-2026

Arcus Biosciences, Inc. filed a DEF 14A proxy statement dated April 21, 2026, for its virtual Annual Meeting of Stockholders on June 11, 2026, at 8:30 a.m. PT, with 125,628,682 shares of common stock outstanding as of the April 16, 2026 record date. Stockholders will vote on electing four Class II director nominees to serve until the 2029 annual meeting, ratifying Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and approving named executive officer compensation on an advisory basis. No financial performance metrics or period-over-period changes are disclosed in the provided filing content.

• ·Annual Meeting conducted entirely virtually via live webcast at www.virtualshareholdermeeting.com/RCUS2026 using 16-digit control number.
• ·Stockholder list available for examination 10 days prior to meeting at corporate headquarters (3928 Point Eden Way, Hayward, CA 94545) or during the meeting online.
• ·Proxy materials and Annual Report (Form 10-K for year ended December 31, 2025) available at www.proxyvote.com.

21-04-2026

Capital One Financial Corporation filed a Form 8-K on April 21, 2026, furnishing monthly charge-off and delinquency metrics as of and for the month ended March 31, 2026, under Regulation FD Disclosure (Item 7.01). The metrics are detailed in Exhibit 99.1, which is not deemed 'filed' for liability purposes under Section 18 of the Exchange Act. No specific numerical data on charge-offs or delinquencies is included in the filing body.

• ·Filing covers metrics as of and for the month ended March 31, 2026
• ·Securities registered on New York Stock Exchange
• ·Incorporated in Delaware, IRS EIN 54-1719854

21-04-2026

CoreWeave, Inc. (Nasdaq: CRWV) announced its intention to offer $1,000 million aggregate principal amount of 9.750% senior notes due 2031 in a private offering, subject to market conditions. These notes will be additional under the April 14, 2026 Indenture, following the prior issuance of $1,750 million of the same notes, and guaranteed by certain wholly-owned subsidiaries. Proceeds are intended for general corporate purposes, including repayment of outstanding indebtedness and related fees.

• ·Notes offered only to qualified institutional buyers under Rule 144A or non-U.S. persons under Regulation S; not registered under Securities Act.
• ·Company established in 2017; completed Nasdaq public listing (CRWV) in March 2025.
• ·Forward-looking statements subject to risks including market conditions and ability to complete offering.

21-04-2026

Spyros Papapetropoulos resigned from Lipocine Inc.'s Board of Directors effective April 16, 2026, where he had served as Chairman, Lead Independent Director, and compensation committee member since 2022, due to competing professional commitments and differing views on the company's strategic direction. The Board appointed R. Dana Ono as the new Chairman and Lead Independent Director on April 20, 2026. No financial or operational impacts from the changes were disclosed.

21-04-2026

Inhibrx Biosciences, Inc. announced updated interim data from its Phase 1/2 study of ozekibart (INBRX-109) in combination with FOLFIRI in 45 evaluable patients with heavily pretreated late-line colorectal cancer, demonstrating an ORR of 20% (historically 1-6% for standard of care), median PFS of 5.5 months with 42% progression-free at 6 months, and DCR of 87%. The safety profile remains manageable, with common TEAEs consistent with FOLFIRI and no significant liver toxicity despite 68% of patients having liver metastases. The company plans FDA meetings in H2 2026 to discuss registrational trials and accelerated pathways, and submitted a BLA for ozekibart in conventional chondrosarcoma in April 2026.

• ·Nearly half of responses durable exceeding 6 months
• ·Responses observed irrespective of RAS/RAF mutation status
• ·Most common TEAEs: diarrhea, fatigue, nausea (Grade 1 or 2)
• ·Corporate presentation posted to investors tab at www.inhibrx.com

21-04-2026

Manhattan Associates reported Q1 2026 revenue of $282.2 million, up 7% YoY from $262.8 million, driven by 24% growth in cloud subscriptions to $117.1 million, though license revenue plummeted 76% to $2.2 million and maintenance revenue dipped 5% to $30.6 million. GAAP diluted EPS declined slightly to $0.82 from $0.85, while non-GAAP adjusted EPS rose to $1.24 from $1.19; RPO grew to $2.35 billion from $2.23 billion at year-end 2025. The company repurchased $150 million in shares and issued FY2026 guidance for 6-7% revenue growth to $1,147-1,157 million and adjusted EPS of $5.29-5.37.

• ·Days Sales Outstanding: 72 days at March 31, 2026 (73 days at Dec 31, 2025)
• ·Share repurchase authority increased to $500M in March 2026; $350M remaining
• ·FY2026 guidance: GAAP operating margin 24.6-24.9%; adjusted 34.9-35.1%

21-04-2026

Financial Consulate, Inc., an investment adviser, filed its quarterly 13F-HR on April 21, 2026, for the period ended March 31, 2026, disclosing sole discretionary voting authority over 1402 equity positions with no reported changes in holdings structure highlighted. Top holdings include Apple Inc. ($19,614,564 for 77,287 shares), Amazon.com Inc. ($2,361,724 for 11,340 shares), and Alphabet Inc. Cap Stk Cl A ($1,770,059 for 6,155 shares), reflecting a diversified portfolio across technology, healthcare, and ETFs. No period-over-period comparisons or performance metrics are provided in the filing.

• ·Filing SEC file number: 028-16386
• ·Filer CIK: 0001624510
• ·Business address: 11019 McCormick Road Suite 200, Hunt Valley, MD 21031
• ·Phone: (410) 823-7283

21-04-2026

Voya Financial, Inc. disclosed preliminary assets under management (AUM) for its Investment Management (IM) segment as of March 31, 2026, totaling approximately $353 billion ahead of its quarterly earnings release scheduled for May 5, 2026. AUM by asset type includes $98 billion of equity assets, $152 billion of fixed income public assets, $86 billion of fixed income private assets, $15 billion of alternative assets, and $3 billion of money market assets. By client type, it comprises $170 billion of institutional external client assets, $147 billion of retail external client assets, and $37 billion of company general account assets.

• ·All external and general account client assets reported on a market value basis.
• ·Quarterly earnings release and financial supplement scheduled for May 5, 2026.

21-04-2026

Triumph Financial reported Q1 2026 net income to common stockholders of $5.6 million, or $0.23 per diluted share, with total Payments revenue growing 2.6% QoQ and 25.8% YoY to $19.1 million despite a seasonal 9.2% QoQ decline in invoice volumes. North Star metrics showed strong YoY Transportation revenue growth of 23.5% and Intelligence gross margin of 86.1%, but Factoring operating margin at 34.7% and Payments EBITDA margin ex-LoadPay at 34.0% remain below long-term targets, while Transportation revenue grew only 0.6% QoQ and PAR dipped 2.3% QoQ.

• ·LoadPay # of accounts grew 36.9% QoQ to 8,065 and 936.6% YoY; active carrier accounts up 26.9% QoQ.
• ·Broker revenue per invoice increased 12.9% QoQ to $1.31.
• ·Average interchange fees declined 3.6% QoQ to 1.62%.
• ·Network Engagement improved to 66.1% (+1.9% QoQ, +15.7% YoY).

21-04-2026

Bridgewater Bancshares reported Q1 2026 net income of $17.4 million, or $0.58 per diluted share, up from $13.3 million ($0.43) in Q4 2025 and $9.6 million ($0.31) in Q1 2025, boosted by net interest margin expansion to 2.99% (+24 bps QoQ, +48 bps YoY) and a $7.3 million pre-tax gain on $208.5 million securities sale. However, total deposits decreased $14.9 million (1.4% annualized QoQ), efficiency ratio rose to 56.3% from 51.6% QoQ, and adjusted net income fell to $12.6 million ($0.41 adjusted EPS) from prior quarter levels. Gross loans grew $58.5 million (5.5% annualized QoQ) and core deposits increased $26.2 million (3.2% annualized QoQ), while asset quality improved with nonperforming assets at 0.22%.

• ·Common Equity Tier 1 Risk-Based Capital Ratio of 9.53% at Mar 31 2026, up from 9.17% at Dec 31 2025.
• ·Tangible book value per share of $15.93 at Mar 31 2026, up 9.9% annualized from Q4 2025.
• ·Provision for credit losses on loans and leases $1.4 million in Q1 2026, vs $1.3 million Q4 2025.
• ·Annualized net loan charge-offs 0.05% of average loans in Q1 2026, down from 0.11% Q4 2025.
• ·Loan to deposit ratio 101.5% at Mar 31 2026, up from 99.7% Dec 31 2025.

21-04-2026

Prudential of Japan (POJ) is extending its voluntary sales suspension by an additional 180 days following the initial 90-day suspension that began on February 9, 2026, due to greater-than-expected complexity in implementing operational, governance, and organizational changes. While existing policyholders and in-force servicing remain unaffected, and POJ is described as financially sound, the extension delays new sales resumption and will be further discussed on a conference call including estimated financial impacts. Reforms target compensation, sales conduct, governance, and the Life Planner model to rebuild trust.

• ·Conference call hosted by Prudential Financial’s Chairman & CEO and CFO on April 21, 2026 at 5:30 p.m. ET
• ·Ongoing independent third-party review of POJ’s management system expected to take several months

21-04-2026

Keystone Financial Group, Inc. filed its 13F-HR on April 21, 2026, disclosing holdings of $192399083 in 13C-eligible securities across 134 positions as of March 31, 2026, all with sole voting and disposition power. Largest positions include VANGUARD MALVERN FDS CORE-PLUS BD ETF at 21173692, ISHARES TR 0-3 MNTH TREASRY at 18142729, and SCHWAB STRATEGIC TR US DIVIDEND EQ at 12013572. No prior period data provided for comparisons.

• ·Filing covers Q1 2026 period ending 03-31-2026
• ·All 134 positions reported as SH SOLE with 0 shared voting/disposition power

21-04-2026

Intuitive Surgical reported Q1 2026 revenue of $2.77 billion, up 23% YoY from $2.25 billion, driven by 17% worldwide procedure growth (da Vinci +16%, Ion +39%), 431 da Vinci system placements (up from 367), and 52 Ion placements (up from 49). GAAP net income rose to $822 million ($2.28 per diluted share) from $698 million ($1.92), while non-GAAP net income increased to $901 million ($2.50 per diluted share) from $662 million ($1.81). Cash, cash equivalents, and investments ended at $7.98 billion, down $1.05 billion due to $1.1 billion share repurchases and a business acquisition.

• ·Q1 2026 da Vinci placements included 243 systems under operating lease arrangements (118 usage-based), vs 198 (107 usage-based) in Q1 2025.
• ·Share-based compensation expense was $213 million in Q1 2026, up from $190 million in Q1 2025.
• ·Excess tax benefits in Q1 2026 GAAP net income were $73 million ($0.20 per diluted share), down from $145 million ($0.40) in Q1 2025.
• ·FY 2026 outlook includes estimated 1.0% tariff impact on non-GAAP gross profit margin.